Osteosarcoma (OS) – Market Insights, Epidemiology and Market Forecast-2028

Albany, Jan 22, 2019 (Issuewire.com) – Osteosarcoma (OS) – Market Insights, Epidemiology and Market Forecast-2028

Osteosarcoma (OS) is a relatively rare tumour of bone with a worldwide prevalence of 3.4 cases per million people per year.

More on StockNewDesk:

  • Osteosarcoma (also called osteogenic sarcoma) is the most common type of cancer that starts in the bones.
  • It is more common in males than in females. Females tend to develop it slightly earlier.
  • About 2% of childhood cancers are osteosarcomas, but they make up a much smaller percentage of adult cancers.
  • In the United States, the prevalence of osteosarcoma is 3.1 per million (4.4 per million population < 25 years). Osteosarcoma is very rare in young children (0.5 cases per million per year in children < 5 years).

(Albany, US) DelveInsight launched a new report on Osteosarcoma (OS) – Market Insights, Epidemiology and Market Forecast-2028

Key topics covered

  • The report provides an in-depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, aetiology, pathophysiology and diagnostic trends.
  • The report provides insights about a historical and current patient pool and forecasted trend for 7 major markets.
  • The report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs.
  • The market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

Request for sample pages

Each year, about 800 to 900 new cases of osteosarcoma are diagnosed in the United States. About half of these are in children and teens. Most osteosarcomas occur in children and young adults between the ages of 10 and 30. Teens are the most commonly affected age group, but people of any age can develop osteosarcoma. About 10% of all osteosarcomas occur in people older than 60.

More on StockNewDesk:

Osteosarcoma is a bone tumour and can occur in any bone, usually in the extremities of long bones near metaphyseal growth plates. The most common sites are as follows: Femur (42%, 75% of which are in the distal femur); Tibia (19%, 80% of which are in the proximal tibia); Humerus (10%, 90% of which are in the proximal humerus); Skull and jaw (8%); Pelvis (8%)The World Health Organizations histologic classification of bone tumors divides OS into Central, Intramedullary; Surface tumours.

In the current market scenario, the standard treatment for Osteosarcoma includes Surgery, Chemotherapy and Radiation therapy. Osteosarcoma is often treated with a combination of therapies that can include surgery, chemotherapy and radiation therapy. Most patients with high-grade tumours receive about three months of chemotherapy, known as neo-adjuvant therapy, before surgery. Chemotherapy such as doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide have antitumor activity in osteosarcoma.

The dynamics of Osteosarcoma market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period of 2019-2028. Companies across the globe are working towards the development of new treatment therapies for Osteosarcoma.

Companies covered

  • Eleison Pharmaceuticals
  • Aadi Bioscience

And  many others

       Drugs covered

  • Inhaled lipid-complexed cisplatin (ILC)
  • ABI-009

And many others

Table of contents

1. Report Introduction

2. OSTEOSARCOMA Market Overview at a Glance

3. Disease Background and Overview: Osteosarcoma (OS)

4. Epidemiology and Patient Population

5. Osteosarcoma: Country- Wise Epidemiology

 5.1. The United States 5.1.1. Prevalent cases of Osteosarcoma in the United States (2017-2028)

5.2. EU-5

5.2.1. Germany  

5.2.2. France

5.2.3. Italy

5.2.4. Spain

5.2.5. United Kingdom

5.3. Japan

6. Treatment & Medical Practices

7. Emerging Therapies

7.1. Key Cross Competition

7.2. Inhaled lipid-complexed cisplatin: Eleison Pharmaceuticals

7.3. ABI-009: Aadi Bioscience

8. Osteosarcoma (OS): Market Size

8.1. Key Findings

8.2. Total 7MM Osteosarcoma Market Analysis

9. 7MM Osteosarcoma (OS): Country-Wise Market Analysis

9.6. Italy

 9.7. Japan

10. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

Shruti Thakur

[email protected]

+919650213330

SOURCE DelveInsight

Media Contact

Shruti

[email protected]

919 321-6187

304 S. Jones Blvd #2432, Las Vegas NV 89107

https://www.delveinsight.com

Source :Delveinsight Business Research LLP

This article was originally published by IssueWire. Read the original article here.

Latest on StockNewDesk:

Login

Lost your password?